NIKKEI 225
23,539.10+27.48(+0.12%)HANG SENG
23,275.53-200.52(-0.85%)CRUDE OIL
39.22-1.38(-3.40%)
Pfizer Inc. (PFE)
36.18 +0.01 (0.03%)
After hours: 4:41PM EDT
| Previous close | 36.39 |
| Open | 36.43 |
| Bid | 36.18 x 4000 |
| Ask | 36.28 x 3000 |
| Day's range | 36.03 - 36.54 |
| 52-week range | 27.88 - 40.97 |
| Volume | 10,972,394 |
| Avg. volume | 26,951,110 |
| Market cap | 200.992B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | 14.32 |
| EPS (TTM) | 2.53 |
| Earnings date | 27 Oct 2020 |
| Forward dividend & yield | 1.52 (4.18%) |
| Ex-dividend date | 05 Nov 2020 |
| 1y target est | 41.79 |
- Editor's pickYahoo Finance
Coronavirus update: World tops 1M deaths; Inovio delays late-stage trial as vaccine race quickens
The coronavirus pandemic neared a grim new milestone of 1 million deaths on Monday, as new diagnoses in the around the world continue to outpace a slowdown in the rate of fatalities.
- Motley Fool
These 2 Biotech Stocks Are Winning the Coronavirus Vaccine Race
Both of these biotechs have performed well this year, but should investors purchase shares of either?
- Business Wire
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight.1 This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.
